STERIS (NYSE:STE) Releases FY 2026 Earnings Guidance

STERIS (NYSE:STE) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 10.150-10.300 for the period, compared to the consensus EPS estimate of 10.220. The company issued revenue guidance of $5.9 billion-$6.0 billion, compared to the consensus revenue estimate of $5.9 billion.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a research report on Friday, January 9th. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $275.20.

STERIS Stock Performance

Shares of STE traded up $2.81 during trading hours on Wednesday, hitting $264.48. The stock had a trading volume of 852,757 shares, compared to its average volume of 525,878. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.63 and a current ratio of 2.37. The firm has a 50-day moving average price of $259.17 and a 200 day moving average price of $249.54. STERIS has a fifty-two week low of $204.90 and a fifty-two week high of $269.44. The firm has a market capitalization of $25.96 billion, a price-to-earnings ratio of 38.00 and a beta of 1.03.

STERIS (NYSE:STE) last released its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 EPS for the quarter, meeting the consensus estimate of $2.53. STERIS had a net margin of 12.07% and a return on equity of 14.43%. The company’s revenue for the quarter was up 9.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.32 EPS. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. As a group, research analysts anticipate that STERIS will post 9.08 EPS for the current year.

STERIS Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 19th. Investors of record on Tuesday, February 17th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date is Tuesday, February 17th. STERIS’s payout ratio is currently 36.21%.

Insiders Place Their Bets

In other STERIS news, VP Julia Madsen sold 5,008 shares of the stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $262.00, for a total transaction of $1,312,096.00. Following the transaction, the vice president owned 10,710 shares in the company, valued at approximately $2,806,020. This represents a 31.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Renato Tamaro sold 5,036 shares of the business’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $257.55, for a total value of $1,297,021.80. Following the completion of the sale, the vice president owned 5,695 shares of the company’s stock, valued at $1,466,747.25. This trade represents a 46.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 25,044 shares of company stock worth $6,586,218. 1.07% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On STERIS

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geneos Wealth Management Inc. raised its position in shares of STERIS by 416.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 104 shares during the period. Advisory Services Network LLC acquired a new position in shares of STERIS in the 3rd quarter valued at $68,000. MUFG Securities EMEA plc purchased a new position in shares of STERIS during the 2nd quarter worth $69,000. Brown Brothers Harriman & Co. increased its position in shares of STERIS by 51.3% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 528 shares of the medical equipment provider’s stock worth $131,000 after purchasing an additional 179 shares during the last quarter. Finally, Peapack Gladstone Financial Corp acquired a new stake in shares of STERIS during the 2nd quarter worth about $200,000. 94.69% of the stock is owned by hedge funds and other institutional investors.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.